Archive
1250 articles, sorted by publication time.
RVX-001 seeks to circumvent capsular-type limitations by using highly conserved bacterial proteins to elicit both antibody and cellular immunity; cross-type protection has been observed in preclinical studies, but human safety and efficacy remain to be determined in clinical trials.
The arbitration tribunal found that PM647 falls within the development scope retained by Prime Medicine under the collaboration agreement and rejected Beam Therapeutics’ requests for damages and injunctive relief. The ruling removes a key legal obstacle, but competition between the two companies over rights to gene-editing tools is not over.
Using literature and multi-omics data, XunZi identified two kinases, CHK2 and IRAK4. Inhibiting CHK2 reduced neuronal loss and improved motor impairments in two types of Parkinson’s disease mouse models, but a long road of validation remains before it can become a human treatment.
This model, which integrates molecular mechanisms with machine learning, not only predicts guide RNA performance but also seeks to circumvent resistance from mismatch repair. The research team achieved correction of more than 40% of the target mutations in the cerebral cortex of neonatal mice, but efficacy, safety, and durability remain to be demonstrated.
The new indication gives MenQuadfi an opportunity to be included in routine infant immunization, but the approval was based mainly on antibody responses rather than a disease-prevention trial; the primary non-inferiority endpoint for serogroup A was also not met.
The new program searches the glioblastoma “dark genome” for antigens shared across patients, aiming to eliminate the burden of producing individualized vaccines; however, the evidence remains limited to a small-sample analysis and in vitro immune responses.
The collaboration, worth up to $110 million, will connect automated cell experiments, multi-omics measurements, and AI models into a target discovery pipeline; however, guaranteed payments, disease scope, and model validation results have not been disclosed.
Tumor-associated macrophages release a neurotrophic factor that guides sensory nerves into tumors; blocking this pathway can suppress tumors in mice, but translation into a human therapy remains a long way off.
The new partnership links more than 300 computational models with synthesis, expression, and testing services, claiming experimental data can be obtained in as little as four days; however, there are currently no independent benchmarks demonstrating the integrated workflow’s speed, success rate, or decision-making benefits.
This intravitreal injection candidate aims to activate the body’s own p21 braking mechanism to prevent abnormal proliferation after retinal detachment surgery; its actual efficacy remains to be determined by the first-in-human study.
Two 72-week pivotal studies will separately enroll adults with overweight or obesity, with and without type 2 diabetes. Although early signals for weight loss and tolerability show potential, they still require evaluation over a longer period and in a larger population.
The ON-SITE study enrolled 1,006 participants and collected more than 3,250 fresh bronchoscopic specimens in preparation for validating an imaging system designed to rapidly identify morphology suspicious for cancer at the point of sampling. However, completed enrollment does not mean its performance has been established; accuracy and clinical impact still await formal results.